Generic medicines : solutions for a sustainable drug market?

Dylst, P. and Vulto, A. and Godman, B. and Simoens, S. (2013) Generic medicines : solutions for a sustainable drug market? Applied Health Economics and Health Policy, 11 (5). pp. 437-443. ISSN 1179-1896

Full text not available in this repository.Request a copy from the Strathclyde author

Abstract

Generic medicines offer equally high-quality treatment as originator medicines do at much lower prices. As such, they represent a considerable opportunity for authorities to obtain substantial savings. At the moment, the pharmaceutical landscape is changing and many pharmaceutical companies have altered their development and commercial strategies, combining both originator and generic divisions. In spite of this, the generic medicines industry is currently facing a number of challenges: delayed market access; the limited price differential with originator medicines; the continuous downwards pressure on prices; and the negative perception regarding generic medicines held by some key stakeholder groups. This could jeopardize the long-term sustainability of the generic manufacturing industry. Therefore, governments must focus on demand-side policies, alongside policies to accelerate market access, as the generic medicines industry will only be able to deliver competitive and sustainable prices if they are ensured a high volume. In the future, the generic medicines industry will increasingly look to biosimilars and generic versions of orphan drugs to expand their business. © 2013 Springer International Publishing Switzerland.

  • Item type:Article
    ID code:50954
    Dates:
    Date
    Event
    October 2013
    Published
    12 July 2013
    Published Online
    Keywords:biosimilar agent, generic drug, hydroxymethylglutaryl coenzyme A reductase inhibitor, orphan drug, proton pump inhibitor, cost control, drug cost, drug industry, drug marketing, government, health care access, health care policy, health care quality, human, perception, reimbursement, review, attitude to health, cost savings, drug costs, drugs, generic, forecasting, humans, marketing, Pharmacy and materia medica, Economics and Econometrics, Health Policy, SDG 3 - Good Health and Well-being
    Subjects:Medicine > Pharmacy and materia medica
    Department:Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
    Depositing user: Pure Administrator
    Date deposited:08 Jan 2015 19:24
    Last modified:15 Sep 2021 17:07
    Related URLs:
    URI:https://strathprints.strath.ac.uk/id/eprint/50954
CORE (COnnecting REpositories)